PL1781640T3 - 2,4-Di-(aminofenylo)-pirymidyny jako inhibitory PLK - Google Patents

2,4-Di-(aminofenylo)-pirymidyny jako inhibitory PLK

Info

Publication number
PL1781640T3
PL1781640T3 PL05777896T PL05777896T PL1781640T3 PL 1781640 T3 PL1781640 T3 PL 1781640T3 PL 05777896 T PL05777896 T PL 05777896T PL 05777896 T PL05777896 T PL 05777896T PL 1781640 T3 PL1781640 T3 PL 1781640T3
Authority
PL
Poland
Prior art keywords
aminophenyl
pyrimidine derivatives
plk inhibitors
plk
inhibitors
Prior art date
Application number
PL05777896T
Other languages
English (en)
Inventor
Ulrich Reiser
Stephan Karl Zahn
Lars Herfurth
Heinz Stadtmueller
Harald Engelhardt
Martin Steegmaier
Anke Baum
Ulrich Guertler
Andreas Schoop
Jens Juergen Quant
Flavio Solca
Rudolf Hauptmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PL1781640T3 publication Critical patent/PL1781640T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL05777896T 2004-08-20 2005-08-18 2,4-Di-(aminofenylo)-pirymidyny jako inhibitory PLK PL1781640T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04019775 2004-08-20
PCT/EP2005/054089 WO2006021544A1 (de) 2004-08-20 2005-08-18 2,4-di(amimopheyl) pyrimidine als plk inhibitoren
EP05777896.1A EP1781640B1 (de) 2004-08-20 2005-08-18 2,4-di(aminophenyl)pyrimidine als plk inhibitoren

Publications (1)

Publication Number Publication Date
PL1781640T3 true PL1781640T3 (pl) 2015-06-30

Family

ID=34926239

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05777896T PL1781640T3 (pl) 2004-08-20 2005-08-18 2,4-Di-(aminofenylo)-pirymidyny jako inhibitory PLK

Country Status (20)

Country Link
US (4) US7521457B2 (pl)
EP (1) EP1781640B1 (pl)
JP (1) JP5060294B2 (pl)
KR (1) KR101277506B1 (pl)
CN (1) CN101044137A (pl)
AR (1) AR051195A1 (pl)
AU (1) AU2005276500B2 (pl)
BR (1) BRPI0514371A (pl)
CA (1) CA2573371C (pl)
DK (1) DK1781640T3 (pl)
ES (1) ES2532611T3 (pl)
HU (1) HUE025285T2 (pl)
IL (1) IL181421A (pl)
MX (1) MX2007002055A (pl)
NZ (1) NZ553632A (pl)
PL (1) PL1781640T3 (pl)
RU (1) RU2404979C2 (pl)
TW (1) TWI421248B (pl)
WO (1) WO2006021544A1 (pl)
ZA (1) ZA200700084B (pl)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200804364A (en) * 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
WO2007115999A1 (en) * 2006-04-10 2007-10-18 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
AR060890A1 (es) * 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
DE102006039003A1 (de) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
GEP20135728B (en) * 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
EP2222647B1 (en) 2006-10-23 2015-08-05 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
AU2008254318B2 (en) * 2007-05-16 2012-04-05 Eli Lilly And Company Triazolyl aminopyrimidine compounds
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AR067413A1 (es) 2007-07-05 2009-10-07 Genentech Inc Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
WO2009010789A2 (en) * 2007-07-16 2009-01-22 Astrazeneca Ab Pyrimidine derivatives 934
NZ583815A (en) 2007-08-14 2012-03-30 Boehringer Ingelheim Int Aryl Sulfonamides with an Analgesic Action
EP2025675A1 (de) 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
MX2010012703A (es) 2008-05-21 2010-12-21 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
SG10201510696RA (en) * 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
KR20110053424A (ko) * 2008-08-12 2011-05-23 베링거 인겔하임 인터내셔날 게엠베하 사이클로알킬-치환된 피페라진 화합물의 제조 방법
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
WO2010072155A1 (zh) * 2008-12-26 2010-07-01 复旦大学 一种嘧啶类衍生物及其制备方法和用途
ES2624622T3 (es) 2008-12-30 2017-07-17 Rigel Pharmaceuticals, Inc. Inhibidores de pirimidindiamina cinasa
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
CA2748414A1 (en) * 2009-04-24 2010-10-28 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
CN102459249A (zh) * 2009-05-22 2012-05-16 埃克塞里艾克西斯公司 作为PI3K/mTOR抑制剂的苯并氧氮杂环庚三烯以及它们使用与制造方法
BRPI1010896A2 (pt) 2009-05-26 2019-09-24 Exelixis Inc benzoxazepinas como inibidores de pi3k/mtor e métodos de seus usos e fabricação
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
ME02847B (me) 2009-07-27 2018-01-20 Gilead Sciences Inc Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
IN2012DN02534A (pl) 2009-09-16 2015-08-28 Avila Therapeutics Inc
US20110269244A1 (en) 2009-12-30 2011-11-03 Petter Russell C Ligand-directed covalent modification of protein
CN103003264B (zh) 2010-05-21 2014-08-06 切米利亚股份公司 嘧啶衍生物
HUE029196T2 (en) 2010-06-04 2017-02-28 Hoffmann La Roche Aminoprimidine derivatives as LRRK2 modulators
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
MY160734A (en) 2010-08-10 2017-03-15 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
NZ710636A (en) 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
SG189043A1 (en) 2010-11-10 2013-05-31 Hoffmann La Roche Pyrazole aminopyrimidine derivatives as lrrk2 modulators
JP6000273B2 (ja) 2010-11-29 2016-09-28 オーエスアイ・ファーマシューティカルズ，エルエルシー 大環状キナーゼ阻害剤
US8546443B2 (en) 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
CA2830129C (en) 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
BR112013027734A2 (pt) 2011-05-04 2017-08-08 Ariad Pharma Inc compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica
ES2648820T3 (es) 2011-05-10 2018-01-08 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de los canales de sodio
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (pl) 2011-07-01 2018-04-28
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
US9242976B2 (en) 2012-01-13 2016-01-26 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2013106612A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
EP2802577B1 (en) 2012-01-13 2017-03-01 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
SMT201800571T1 (it) 2012-03-15 2019-01-11 Celgene Car Llc Sali di un inibitore di chinasi del recettore del fattore di crescita dell’epidermide
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
ES2595222T3 (es) * 2012-10-18 2016-12-28 Bayer Pharma Aktiengesellschaft Derivados de 5-fluoro-N-(piridin-2-il)piridin-2-amina que contienen un grupo sulfona
ES2616812T3 (es) 2012-11-08 2017-06-14 Bristol-Myers Squibb Company Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa
PE20150953A1 (es) 2012-11-08 2015-06-20 Bristol Myers Squibb Co Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
JP6091248B2 (ja) * 2013-02-22 2017-03-08 キヤノン株式会社 プリンタ
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
TW201609693A (zh) 2014-01-03 2016-03-16 必治妥美雅史谷比公司 雜芳基取代之菸鹼醯胺化合物
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
AR105113A1 (es) 2015-06-24 2017-09-06 Bristol Myers Squibb Co Compuestos de aminopiridina sustituida con heteroarilo
UY36747A (es) 2015-06-24 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
US10618903B2 (en) 2015-06-24 2020-04-14 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
CA2992054A1 (en) * 2015-07-29 2017-02-02 Laboratorios Del Dr. Esteve, S.A. Amide derivatives having multimodal activity against pain
TWI724056B (zh) * 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
CN106831730B (zh) * 2017-01-11 2019-11-26 温州医科大学 一种取代的二氨基嘧啶类化合物及其在制备抗恶性肿瘤药物中的用途
MY200228A (en) 2017-05-11 2023-12-15 Bristol Myers Squibb Co Thienopyridines and benzothiophenes useful as irak4 inhibitors
MA50424A (fr) 2018-01-08 2020-08-26 Chemocentryx Inc Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2
WO2021011724A1 (en) 2019-07-18 2021-01-21 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
WO2021011727A1 (en) 2019-07-18 2021-01-21 Bristol-Myers Squibb Company PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
CN114174279B (zh) 2019-08-06 2024-07-02 百时美施贵宝公司 可用作irak4抑制剂的双环杂环化合物
US12570659B2 (en) 2019-08-13 2026-03-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds useful as IRAK4 inhibitors
WO2021113689A1 (en) * 2019-12-06 2021-06-10 Yale University Spak/osr inhibitors and methods of using same
US12391702B2 (en) 2020-02-03 2025-08-19 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
CN115335380B (zh) 2020-02-03 2024-08-02 百时美施贵宝公司 可用作irak4抑制剂的三环杂芳基化合物
JP2024502175A (ja) * 2021-01-07 2024-01-17 オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） Ｎｕａｋキナーゼの阻害剤としてのイソインドリノンアミノピリミジン化合物、その組成物及び使用
MX2024010431A (es) * 2022-02-28 2024-09-05 Wigen Biomedicine Tech Shanghai Co Ltd Compuesto como inhibidor de fak y uso del mismo.
WO2024051717A1 (zh) * 2022-09-08 2024-03-14 上海深势唯思科技有限责任公司 作为plk1抑制剂的化合物及其制备方法和用途
CN119285624B (zh) * 2024-09-25 2025-09-23 南方医科大学中西医结合医院 一种含噻吩的嘧啶类化合物及其制备方法与在制备具有抗癌作用的药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU194829A1 (ru) * 1966-07-08 1967-04-12 Замещенных 5,6-дигидропирроло-
US4653487A (en) * 1986-01-29 1987-03-31 Maale Gerhard E Intramedullary rod assembly for cement injection system
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
MXPA02007957A (es) * 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
CN1427700B (zh) * 2000-04-05 2010-04-21 科丰有限公司 治疗骨折和/或病骨的方法和装置
US6749595B1 (en) * 2000-06-15 2004-06-15 Kieran P. J. Murphy Cement delivery needle
US7144414B2 (en) * 2000-06-27 2006-12-05 Smith & Nephew, Inc. Surgical procedures and instruments
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6595998B2 (en) * 2001-03-08 2003-07-22 Spinewave, Inc. Tissue distraction device
US20020188300A1 (en) * 2001-06-06 2002-12-12 Arramon Yves P. Cannula system for hard tissue implant delivery
US6679890B2 (en) * 2001-08-28 2004-01-20 Joseph Y. Margulies Method and apparatus for augmentation of the femoral neck
JP3993855B2 (ja) * 2001-11-01 2007-10-17 スパイン・ウェイブ・インコーポレーテッド 脊椎椎間板の回復のための装置
US6582439B1 (en) * 2001-12-28 2003-06-24 Yacmur Llc Vertebroplasty system
WO2004043936A1 (ja) * 2002-11-14 2004-05-27 Kyowa Hakko Kogyo Co., Ltd. Ｐｌｋ阻害剤
US7514446B2 (en) 2003-02-20 2009-04-07 Smithkline Beecham Corporation Pyrimidine compounds
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
BR122019017579B8 (pt) * 2003-08-15 2021-07-27 Novartis Ag 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica
EP2305155A3 (en) * 2003-10-23 2015-01-14 TRANS1, Inc. Tools and tool kits for performing minimally invasive procedures on the spine
US7699852B2 (en) * 2003-11-19 2010-04-20 Zimmer Spine, Inc. Fenestrated bone tap and method
US8197666B2 (en) * 2003-11-28 2012-06-12 Maria Roiner Method and apparatus for the manufacture of one or more gases
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
US7513901B2 (en) * 2005-05-19 2009-04-07 Warsaw Orthopedic, Inc. Graft syringe assembly
US20070162043A1 (en) * 2005-09-01 2007-07-12 Csaba Truckai Methods for sensing retrograde flows of bone fill material
US7901409B2 (en) * 2006-01-20 2011-03-08 Canaveral Villegas Living Trust Intramedullar devices and methods to reduce and/or fix damaged bone

Also Published As

Publication number Publication date
US20060148800A1 (en) 2006-07-06
NZ553632A (en) 2010-12-24
US7521457B2 (en) 2009-04-21
DK1781640T3 (en) 2015-04-20
MX2007002055A (es) 2007-03-29
AU2005276500A1 (en) 2006-03-02
BRPI0514371A (pt) 2008-06-10
EP1781640B1 (de) 2015-01-07
JP2008510691A (ja) 2008-04-10
KR101277506B1 (ko) 2013-06-25
TW200619218A (en) 2006-06-16
RU2007109870A (ru) 2008-11-10
US20090149438A1 (en) 2009-06-11
CA2573371A1 (en) 2006-03-02
JP5060294B2 (ja) 2012-10-31
US20090163465A1 (en) 2009-06-25
ZA200700084B (en) 2008-02-27
IL181421A0 (en) 2007-07-04
ES2532611T3 (es) 2015-03-30
KR20070048757A (ko) 2007-05-09
WO2006021544A1 (de) 2006-03-02
RU2404979C2 (ru) 2010-11-27
AU2005276500B2 (en) 2012-05-10
HUE025285T2 (en) 2016-03-29
AR051195A1 (es) 2006-12-27
IL181421A (en) 2015-05-31
EP1781640A1 (de) 2007-05-09
TWI421248B (zh) 2014-01-01
CN101044137A (zh) 2007-09-26
US20110086842A1 (en) 2011-04-14
CA2573371C (en) 2013-02-19

Similar Documents

Publication Publication Date Title
PL1781640T3 (pl) 2,4-Di-(aminofenylo)-pirymidyny jako inhibitory PLK
IL183706A0 (en) 2,4(4,6) pyrimidine derivatives
SG153875A1 (en) Pyrimidine urea derivatives as kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
SI1497019T1 (sl) Pirolo-triazin anilin spojine uporabne kot inhibitorji kinaze
IS7534A (is) Pýrazóló-pýrimídín anilín efnasambönd, gagnleg sem kínasatálmar
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
IL191711A0 (en) 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
EP1951715A4 (en) AMINOPYRIMIDINES USEFUL AS INHIBITORS OF KINASES
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
IL195218A0 (en) 2,4-diamino pyrimidines as cell cycle kinase inhibitors
PL1763517T3 (pl) Pochodne pirymidyny jako inhibitory 11BETA-HSD1
ZA200703835B (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ZA200709919B (en) Pyrrol (2,3-B) pyridine derivatives protein kinase inhibitors
ZA200804768B (en) Aminopyrimidines useful as kinase inhibitors
ZA200803288B (en) Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors
HK1121740A (en) Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors
ZA200609510B (en) Pyrimidine urea derivatives as kinase inhibitors
SI1483265T1 (sl) Drivati purina kot inhibitoriji kinaze